We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Orlistat (Xenical 120 mg Rx / Alli 60 mg OTC) — gastrointestinal lipase inhibitor
A gastrointestinal lipase inhibitor that blocks roughly 30% of dietary fat from being absorbed. It is the only weight-loss drug sold both on prescription (Xenical 120 mg) and over the counter (Alli 60 mg). The evidence base is large and old: across 16 long-term randomised trials it produces about 2.9 kg more weight loss than placebo, and in the 4-year XENDOS trial it cut new type 2 diabetes from 9.0% to 6.2%, though exploratory analysis found the effect was detectable ONLY in the ~21% of participants who already had impaired glucose tolerance. The trade-off is that the unabsorbed fat leaves in the stool — oily spotting, faecal urgency and steatorrhoea — and it measurably impairs fat-soluble vitamin absorption, which is what drives its real drug interactions (warfarin, levothyroxine, ciclosporin). Modest, unglamorous, and hard to stay on.
Prescription medication — not a dietary supplement
Orlistat is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Orlistat studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2017 with a typical study size of 688 participants.
Based on 12 studies · 3 meta-analyses · 4 RCTs · 5,293 total participants
Confidence
High confidenceBy outcome
1 more outcome with fewer studies not shown.
Orlistat has one of the deepest randomised evidence bases of any weight-management agent — two pivotal 2-year placebo-controlled trials, a 4-year hard-outcome trial (XENDOS) showing reduced type 2 diabetes incidence, a dedicated diabetes trial, and two meta-analyses independent of each other (though both carry author conflicts with anti-obesity drug makers) that agree closely on the effect size. That consistency is why it scores in the middle rather than the bottom band. What holds it down is that the effect is small (2.6–2.9 kg vs placebo, last of the five long-term-approved agents in network meta-analysis), attrition in the trials ran 30–45%, and the tolerability and nutritional cost is high: steatorrhoea and faecal urgency, measurable fat-soluble vitamin depletion, absorption interactions with warfarin/levothyroxine/ciclosporin, and rare oxalate nephropathy. It works, reliably, by a little.
Orlistat (tetrahydrolipstatin) is a covalent inhibitor of gastric and pancreatic lipase that acts entirely inside the gut lumen. By blocking the enzymes that hydrolyse triglycerides into absorbable free fatty acids, it prevents roughly 30% of ingested dietary fat from being absorbed at all (Davidson 1999); that fat is simply passed in the stool. It is minimally systemically absorbed, so unlike appetite-suppressant weight drugs it has no central nervous system activity — its entire effect and its entire side-effect profile are gastrointestinal and nutritional. Xenical (120 mg three times daily with fat-containing meals) is prescription-only; Alli (60 mg three times daily) was approved for over-the-counter sale, which is unusual for a weight-loss drug and is why clinicians see it taken unsupervised.
The efficacy evidence is unusually deep for a weight drug, and unusually modest in size. The pivotal 2-year European trial (Sjöström 1998, 688 randomised) showed 10.2% body-weight loss on orlistat vs 6.1% on placebo at year 1, with half as much regain during year 2. The 2-year US trial (Davidson 1999, 892 randomised) found 8.76 kg vs 5.81 kg at year 1 and 35.2% regain on 120 mg vs 63.4% on placebo in year 2. In obese people with type 2 diabetes on sulfonylureas (Hollander 1998, n=391), orlistat produced 6.2% vs 4.3% weight loss with significant HbA1c and fasting-glucose improvement and sulfonylurea dose reductions. The largest and longest trial, XENDOS (Torgerson 2004, n=3,305, 4 years), is the hard outcome: cumulative type 2 diabetes incidence 6.2% with orlistat vs 9.0% with placebo, a 37.3% relative risk reduction — though exploratory analysis showed the entire preventive effect sat in the 21% of participants with impaired glucose tolerance at baseline.
Pooled, the number is small and should be quoted honestly. The BMJ meta-analysis of 16 orlistat trials (n=10,631) put the placebo-subtracted weight loss at 2.9 kg (95% CI 2.5 to 3.2) at one year or more (Rucker 2007). The JAMA network meta-analysis of all five long-term-approved agents (Khera 2016, 28 RCTs, 29,018 patients) put orlistat's excess weight loss at 2.6 kg (95% CrI −3.04 to −2.16) and ranked it last of the five on the probability of achieving ≥5% weight loss (44% of patients vs a 23% placebo median; OR 2.70, 95% CrI 2.34–3.09; SUCRA 0.22). Attrition was high — Rucker reports 30–40% and Khera 30–45% — across the trials, and even inside the tightly supervised XENDOS trial only 52% of the orlistat arm completed four years — a completion rate that, tellingly, still beat placebo's 34%.
The safety story is where orlistat is genuinely distinctive. Unabsorbed fat causes oily stools, faecal spotting, flatus with discharge, faecal urgency and abdominal pain — very common early, and the dominant reason people stop. Because the same mechanism blocks lipid-phase absorption generally, it lowers fat-soluble vitamin status: in a controlled paediatric study, vitamin E (alpha-tocopherol) absorption fell significantly and mean vitamin D levels dropped significantly within one month despite a daily multivitamin containing 400 IU of vitamin D (McDuffie 2002). That is also the route to its clinically important drug interactions — orlistat interferes with warfarin, amiodarone, ciclosporin and thyroxine absorption (Filippatos 2008), with a published case of a rising INR on warfarin after orlistat was added (MacWalter 2003) and cases of subtherapeutic ciclosporin in transplant recipients that persisted even with 2-hour dose separation (Barbaro 2002). Two rarer harms are real: orlistat-induced oxalate nephropathy, where fat malabsorption forms calcium soaps in the gut, frees dietary oxalate for absorption, and deposits calcium oxalate in the kidney (Solomon 2017; Filippatos 2008), and post-marketing reports of severe liver injury that prompted regulatory labelling changes — although an integrated analysis of over 10,000 trial subjects — authored entirely by GlaxoSmithKline, which marketed the OTC 60 mg product — found no ALT signal (OR 1.09, 95% CI 0.93–1.28) though total bilirubin WAS raised (OR 1.24, 95% CI 1.03–1.49), and concluded idiosyncratic injury is likely extremely rare (Morris 2012).
Orlistat is a drug, not a supplement. It is listed here because it is bought over the counter alongside supplements, because the fat-soluble vitamin interaction is a genuine concern for anyone taking vitamin A, D, E or K, and because its honest effect size — roughly 3 kg — is a useful benchmark against which other weight-management claims can be read.
Orlistat is a potent, specific inhibitor of intestinal lipases (Filippatos 2008). By blocking hydrolysis of dietary triglycerides into absorbable free fatty acids, it reduces dietary fat absorption by approximately 30% (Davidson 1999), creating a calorie deficit at the level of the gut rather than the brain.
The drug works inside the intestinal lumen and is minimally absorbed systemically, so it has no central appetite or stimulant activity. Its entire benefit and its entire adverse-effect profile are gastrointestinal and nutritional (Filippatos 2008).
The fat that is not absorbed leaves in the stool, producing oily stools, faecal spotting, flatus with discharge, diarrhoea and abdominal pain (Filippatos 2008). These were significantly increased versus placebo in the pivotal trials (Sjöström 1998).
Because vitamins A, D, E and K and several drugs are absorbed in the lipid phase, blocking fat absorption lowers their uptake. Vitamin E absorption fell significantly and mean vitamin D fell significantly within one month of orlistat despite a daily 400 IU multivitamin (McDuffie 2002), and orlistat interferes with the absorption of warfarin, amiodarone, ciclosporin and thyroxine (Filippatos 2008).
Unabsorbed fatty acids bind luminal calcium as soaps, leaving dietary oxalate free to be absorbed. The resulting hyperoxaluria can deposit calcium oxalate in the kidney and cause acute kidney injury or chronic kidney disease (Filippatos 2008; Solomon 2017).
How Orlistat works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
High risk. Orlistat both reduces vitamin K absorption and interferes with warfarin absorption; a documented case required warfarin to be withheld and the dose lowered after orlistat was added (MacWalter 2003). Do not start or stop orlistat without an INR monitoring plan.
Avoid unless closely supervised — subtherapeutic ciclosporin has been reported despite 2-hour dose separation and dose reduction, with graft-rejection risk (Barbaro 2002).
Separate doses and recheck TSH after starting or stopping orlistat; orlistat interferes with thyroxine absorption (Filippatos 2008).
Caution. Reported orlistat oxalate nephropathy occurred against a background of chronic kidney disease, and the mechanism (enteric hyperoxaluria from fat malabsorption) applies to everyone taking it (Solomon 2017; Filippatos 2008). Monitor renal function.
Benefit is real — significant HbA1c and fasting-glucose improvement with sulfonylurea dose reductions (Hollander 1998) — but that means antidiabetic doses may need to be reduced to avoid hypoglycaemia.
Vitamin D fell significantly within one month even on a supervised daily multivitamin in obese adolescents; monitor vitamin D concentrations (McDuffie 2002).
In XENDOS the diabetes-prevention benefit was explained entirely by the impaired-glucose-tolerance subgroup; weight loss was similar in both groups but the diabetes effect was not (Torgerson 2004).
Orlistat interferes with warfarin absorption and reduces absorption of vitamin K, the cofactor warfarin antagonises. A published case reported a rising INR after orlistat was added to stable warfarin therapy, rated 'probable' on the Naranjo scale, requiring warfarin to be withheld and the dose reduced (MacWalter 2003; Filippatos 2008). Monitor INR closely on starting, changing or stopping orlistat.
Orlistat interferes with thyroxine absorption and can reduce its bioavailability and effectiveness (Filippatos 2008). Separate the doses and monitor TSH after starting or stopping orlistat.
A transplant recipient developed subtherapeutic plasma ciclosporin after starting orlistat 360 mg/day; the subtherapeutic levels persisted despite dosing orlistat 2 hours before ciclosporin and despite reducing orlistat to 240 mg/day, and six similar cases had been reported previously (Barbaro 2002; Filippatos 2008). Loss of immunosuppression risks graft rejection — monitor ciclosporin concentrations closely.
Orlistat interferes with amiodarone absorption, affecting its bioavailability and effectiveness (Filippatos 2008). Monitor for loss of rhythm control.
Orlistat reduces fat-soluble vitamin absorption. Vitamin E absorption fell significantly and mean vitamin D fell significantly after one month even with a daily multivitamin containing 400 IU vitamin D (McDuffie 2002). Take fat-soluble vitamins at least 2 hours from any orlistat dose, and monitor vitamin D status.
Tip: Driven directly by dietary fat load — keeping fat to roughly 30% of calories and spread across meals reduces it. Worst in the first weeks. This is the dominant reason people stop the drug.
Tip: Reported as mild-to-moderate gastrointestinal adverse effects of orlistat (Filippatos 2008) and significantly more frequent than placebo in the pivotal trials (Sjöström 1998). Reduce fat intake; severe diarrhoea also impairs absorption of co-administered drugs (Barbaro 2002).
Tip: Mean vitamin D fell significantly within one month despite a daily 400 IU multivitamin (McDuffie 2002). Monitor 25(OH)D and dose vitamin D separately from orlistat, at bedtime. Frequency is not established: the only cited source is a 17-person open-label pilot in adolescents.
Tip: Acute alpha-tocopherol absorption was significantly reduced versus baseline, though serum vitamin E did not change significantly over 3–6 months (McDuffie 2002). Separate supplemental vitamin E from orlistat dosing.
Tip: Two patients developed kidney failure from renal oxalate deposition on orlistat, with partial recovery of kidney function after stopping; the authors argue all patients on orlistat are at risk and that kidney-function monitoring is warranted (Solomon 2017). Maintain hydration; check renal function periodically, especially with pre-existing kidney disease.
Tip: A few such cases have been reported (Filippatos 2008), and post-marketing reports prompted changes to the product information. Against that, an integrated analysis of over 10,000 trial subjects — conducted by the manufacturer of the OTC product — found no ALT signal (OR 1.09, 95% CI 0.93–1.28) but a raised total bilirubin (OR 1.24, 95% CI 1.03–1.49), and concluded idiosyncratic liver injury is likely extremely rare (Morris 2012). Stop and seek care for jaundice, dark urine, right-upper-quadrant pain or unexplained fatigue. That analysis was conducted by the manufacturer of the OTC product.
Tip: Meta-analysis found orlistat slightly lowered HDL cholesterol while improving total and LDL cholesterol, blood pressure and glycaemic control (Rucker 2007). Usually not clinically actionable.
Orlistat has an evidence score of 6/10 — moderate evidence based on 12 indexed studies, including 3 meta-analyses. A gastrointestinal lipase inhibitor that blocks roughly 30% of dietary fat from being absorbed. It is the only weight-loss drug sold both on prescription (Xenical 120 mg) and over the counter (Alli 60 mg). The evidence base is large and old: across 16 long-term randomised trials it produces about 2.9 kg more weight loss than placebo, and in the 4-year XENDOS trial it cut new type 2 diabetes from 9.0% to 6.2%, though exploratory analysis found the effect was detectable ONLY in the ~21% of participants who already had impaired glucose tolerance. The trade-off is that the unabsorbed fat leaves in the stool — oily spotting, faecal urgency and steatorrhoea — and it measurably impairs fat-soluble vitamin absorption, which is what drives its real drug interactions (warfarin, levothyroxine, ciclosporin). Modest, unglamorous, and hard to stay on. Representative study: PMID 18006966.
The commonly studied dose of Orlistat is Prescription Xenical: 120 mg three times daily (360 mg/day), taken with or up to 1 hour after each main fat-containing meal. Over-the-counter Alli: 60 mg three times daily (180 mg/day). Skip the dose if a meal is missed or contains no fat. Used alongside a reduced-calorie diet in which fat supplies roughly 30% of energy — a higher-fat meal makes the gastrointestinal side effects markedly worse, not the weight loss better.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Orlistat is with meals. Take it with food. Orlistat inhibits lipase in the gut lumen, so it only works on fat that is present at the same time.
Orlistat should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are oily stools, oily/faecal spotting and flatus with discharge, diarrhoea, faecal urgency and abdominal pain, reduced vitamin D status. Use caution if any of these apply to you: Chronic malabsorption syndrome; Cholestasis; Pregnancy — intentional weight loss is not a therapeutic goal in pregnancy, and orlistat measurably lowers vitamin D and impairs vitamin E and K absorption (McDuffie 2002).
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Alpha Lipoic Acid
Likely helpsUniversal antioxidant that works in both water and fat, supporting blood sugar control, nerve health, and cellular energy.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 12 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research